Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
In development
Reference number: GID-TA11500
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. More information on timelines will be available in due course.